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AbstrACt
Objective To determine whether a change in editorial 
policy, including the implementation of a checklist, has 
been associated with improved reporting of measures 
which might reduce the risk of bias.
Methods The study protocol has been published at doi: 
10.1007/s11192-016-1964-8.
Design Observational cohort study.
Population Articles describing research in the life 
sciences published in Nature journals, submitted after 1 
May 2013.
Intervention Mandatory completion of a checklist during 
manuscript revision.
Comparators (1) Articles describing research in the 
life sciences published in Nature journals, submitted 
before May 2013; and (2) similar articles in other journals 
matched for date and topic.
Primary outcome The primary outcome is change in the 
proportion of Nature articles describing in vivo research 
published before and after May 2013 reporting the ‘Landis 
4’ items (randomisation, blinding, sample size calculation 
and exclusions). We included 448 Nature Publishing Group 
(NPG) articles (223 published before May 2013, and 225 
after) identified by an individual hired by NPG for this specific 
task, working to a standard procedure; and an independent 
investigator used PubMed ‘Related Citations’ to identify 448 
non-NPG articles with a similar topic and date of publication 
from other journals; and then redacted all articles for time-
sensitive information and journal name. Redacted articles 
were assessed by two trained reviewers against a 74-item 
checklist, with discrepancies resolved by a third.
results 394 NPG and 353 matching non-NPG articles 
described in vivo research. The number of NPG articles 
meeting all relevant Landis 4 criteria increased from 
0/203 prior to May 2013 to 31/181 (16.4%) after (two-
sample test for equality of proportions without continuity 
correction, Χ²=36.2, df=1, p=1.8×10−9). There was no 
change in the proportion of non-NPG articles meeting all 
relevant Landis 4 criteria (1/164 before, 1/189 after). There 
were more substantial improvements in the individual 
prevalences of reporting of randomisation, blinding, 
exclusions and sample size calculations for in vivo 
experiments, and less substantial improvements for in vitro 
experiments.
Conclusion There was an improvement in the reporting of 
risks of bias in in vivo research in NPG journals following a 
change in editorial policy, to a level that to our knowledge 
has not been previously observed. However, there remain 
opportunities for further improvement.
bACkgrOunD
Few articles describing in vivo research report 
taking specific actions designed to reduce 
the risk that their findings are confounded 
by bias,1 and those that do not report such 
actions give inflated estimates of biological 
effects.2 3 Strategies and guidelines which 
might improve the quality of reports of in vivo 
research have been proposed,4 5 and while 
these have been endorsed by a large number 
of journals there is evidence that this endorse-
ment has not been matched by a substantial 
increase in the quality of published reports.6 
Poor replication of in vivo and in vitro 
research has been reported,7–9 and this has 
been attributed in part to poor descriptions 
of the experimental and analytical details.
In May 2013, Nature journals announced 
a change in editorial policy which required 
authors of submissions in the life sciences 
to complete a checklist, during manuscript 
revision, indicating whether or not they had 
taken certain measures which might reduce 
the risk of bias and to report key experimental 
and analytical details, and in their submission 
to detail where in the manuscript these issues 
were addressed.10 The development of this 
checklist was prompted in part by a consensus 
statement5 setting out key aspects of study 
design and conduct which were necessary 
to allow the reader to assess the validity of 
the findings presented; it identified these as 
strengths and limitations of this study
 ► Prospective study with articulated protocol and 
statistical analysis plan, registered with the Open 
Science Framework. 
 ► Study Dataset and code available in public domain.
 ► Involvement of a large collaborative group of out-
come assessors. 
 ► Articulation, in advance of analysis, of smallest ef-
fect size of interest.
 ► Retrospective observational study. 
 ► Limited agreement between outcome assessors. 
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randomisation, blinding, sample size estimation and data 
handling (the ‘Landis 4’). The Nature journals’ check-
list also included items relating to figures and statistical 
representation of data; reagents used; species, strain 
and sex of experimental animals; reporting of relevant 
ethical approvals; consent (for research involving human 
subjects); data deposition; and availability of any bespoke 
computer code. The full checklist is given in online 
supplementary appendix 1. 
The aim of this study was to determine whether the 
implementation of this checklist for submissions has 
been associated with improved reporting of measures 
that might reduce the risk of bias. Because the Landis 
consensus statement drew attention to randomisation, 
blinding, sample size estimation and data handling as 
being the most important items to report, we chose the 
reporting of these as our primary measure of outcome. 
To establish whether any observed change in quality was 
simply a secular trend occurring across all journals, we 
matched each included publication with a publication in 
a similar subject area published at around the same time 
by a different publisher.
MethODs
The methods are described in detail in the published 
study protocol,11 and the data analysis plan and anal-
ysis code were articulated prior to database lock and 
registered on the Open Science Framework (DOI: 
10.17605/OSF.IO/HC7FK). The complete study data set 
including PubMed IDentifiers (PMIDs) and data descrip-
tors (but not, for copyright reasons, the source pdfs) of 
the included articles is available on Figshare (10.6084/
m9.figshare.6226718).
In this observational cohort study, we aimed to deter-
mine whether the implementation of a checklist for 
submissions has been associated with improved reporting 
of measures which might reduce the risk of bias. To do 
this we assessed whether—in the view of trained asses-
sors—manuscripts reported the details required by the 
checklist. Importantly, we did not have access to the 
checklists completed by the authors.
The study populations comprised (1) published arti-
cles accepted for publication in Nature journals which 
described research in the life sciences and which were 
submitted after 1 May 2013 (when the mandatory comple-
tion of a checklist at the stage of manuscript revision was 
introduced) and before 1 November 2014; (2) published 
articles accepted for publication in Nature journals in 
the months preceding May 2013 which describe research 
in the life sciences; and (3) articles from other journals 
matched for subject area and time of publication. We 
measured the change in the reporting of items included 
in the checklist.
Identification of relevant articles
We included studies which described in vivo (articles 
that contain at least one non-human animal experiment, 
including rodents, flies, worms, zebrafish and so on) or in 
vitro research.
NPG articles
One individual was specifically employed by the Nature 
Publishing Group (NPG) to select studies which 
(1) described in vivo or in vitro research and (2) 
were published in Nature, Nature Neurology, Nature Immu-
nology, Nature Cell Biology, Nature Chemical Biology, Nature 
Biotechnology, Nature Methods, Nature Medicine or Nature 
Structural & Molecular Biology. First, the individual iden-
tified papers accepted for publication with an initial 
submission date later than 1 May 2013. Beginning with the 
then-current issues (volume corresponding to year 2015), 
they worked backwards in time, ensuring the submission 
date was after 1 May 2013, collecting papers with the inten-
tion of identifying 40 Nature papers and 20 from each of 
the other 8 titles (ie, 200 papers in total) (‘Post interven-
tion’ group). They then used a similar process to iden-
tify papers submitted for publication before 1 May 2013, 
matched for journal and for country of origin (based on 
the address of the corresponding author), starting with 
the May 2013 issue and working backwards, ensuring 
that the date of submission was after 1 May 2011 (‘pre-in-
tervention’ group). We sought to match on country of 
origin because at that time there was considerable discus-
sion of national and regional differences in the quality 
of research publications (on the basis of anecdote rather 
than experience), and in an attempt to balance ‘writing 
in a foreign language’ between the two groups. Where 
no match could be found with a submission date after 1 
May 2011 (ie, in a 2-year period), then the non-matched 
postintervention publication was excluded from analysis 
and a replacement postintervention publication selected, 
as above. A matching preintervention publication was 
then identified, as described above. Articles describing 
research involving only human subjects were excluded. A 
Nature editorial administrator independent of publishing 
decisions reviewed articles selected against the inclu-
sion criteria and found some (less than 10%) had been 
included incorrectly; they replaced these with manuscript 
pairs that they selected according to the inclusion algo-
rithm described above. The published files corresponding 
to the publication pdfs (including the extended methods 
section, extended data and other supplementary mate-
rials) were used to generate pdfs for analysis. These were 
provided to a member of our research team (RM) at a 
different institution, who used Adobe Acrobat to redact 
information relating to author names or affiliations, 
dates, volumes or page numbers, and the reference list, 
to minimise awareness of outcome assessors to whether 
the manuscript was preintervention or postintervention.
Non-NPG articles
The same member of our research team (RM) was respon-
sible for identifying matching articles in other journals. 
Using PubMed, she entered the NPG publication title to 
retrieve the relevant record. She then added the ‘related 
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citations for PubMed’ result to the search builder. In the 
second line search field of the search builder, she searched 
for ‘Date of publication’ in the same calendar month and 
year and performed the search. In the results returned 
she started with the first result returned and established 
whether it was published in a participating NPG journal 
(given in bold in table 1). If it was not, she applied the 
study inclusion criteria (in vivo or in vitro research or 
both, as defined above), ensuring that there was a match 
on the in vivo/in vitro status between the index NPG 
publication and the non-NPG publication. Where these 
criteria were met, she selected the publication for the 
study and retrieved the pdf, through open access, online 
institutional subscription, interlibrary loan or by request 
from the authors. If the first related citation did not fulfil 
these criteria, she moved to the next, until an appropriate 
publication was found. If an appropriate publication was 
not found, she repeated these steps but with the date 
of publication used in the search extended by 1 month 
earlier and 1 month later. If this process did not identify 
an eligible publication, she again extended the search by 
a month in each direction and continued until a matching 
publication was found. She then recorded the difference 
in calendar months between the date of publication of 
the index NPG article and the date of publication of the 
matching non-NPG article. She then used Adobe Acrobat 
to redact information relating to author names or affil-
iations, dates, volumes or page numbers, and the refer-
ence list, to minimise awareness of outcome assessors to 
whether the manuscript was preintervention or postint-
ervention. Having completed these tasks she played no 
further part in the study.
We anticipated difficulty in identifying matching arti-
cles, and in particular in matching non-NPG articles by 
country; we did not seek to do so. In total 896 articles 
were selected for analysis.
Outcome assessment
The Nature checklist focused on transparency in reporting 
and availability of materials and code, reflected in 10 items. 
We designed a series of questions (online supplementary 
appendix 2) to establish whether a given publication met 
or did not meet the requirements of the checklist. We did 
this to aid outcome assessors, because many checklist items 
included more than one embedded criteria. For instance, the 
section on ‘Figures and Statistical Representation of Data’ 
was operationalised to 12 individual ‘present/absent/not 
applicable’ responses. The checklist relates to the reporting 
of experiments, and so compliance could be achieved by 
reporting whether or not an element was described. For 
instance, for assessment of outcome, a publication was 
considered compliant if it reported that assessment was 
conducted blinded to experimental group, or if it reported 
that assessment was conducted without blinding to exper-
imental group. A manuscript was only considered not to 
fulfil the requirements of the checklist if it described neither 
that the assessment was performed blinded to experimental 
Table 1 Sources of articles included in the study
Journal n 
Nature 89
PLoS One 47
Nature Neuroscience 45
Nature Medicine 44
Nature Immunology 44
Nature Cell Biology 44
Nature Methods 43
Nature Genetics 40
Nature Biotechnology 40
Nature Chemical Biology 35
 Proceedings of the National Academy of 
Sciences of the United States of America 24
Nature Structural & Molecular Biology 19
 Journal of Neuroscience 19
 Journal of Biological Chemistry 13
 Journal of Immunology 13
 Developmental Biology 9
 Neuron 7
 Cell Reports 7
 Journal of Virology 7
 Blood 6
 Immunity 6
 Cell 6
 Gastroenterology 6
 PLoS Genetics 5
 Circulation Research 5
 Biochemical and Biophysical Research 
Communications 5
 EMBO Journal 4
 Biological Psychiatry 4
 Biochimica et Biophysica Acta 4
 FASEB Journal 4
 Genome Research 4
 Development 4
 Human Molecular Genetics 3
 American Journal of Pathology 3
 Journal of Cell Science 3
 Stem Cells and Development 3
 Experimental Neurology 3
 Journal of Neuroscience Methods 3
 Molecular Cell 3
 European Journal of Immunology 3
 Journal of Pharmacology and Experimental 
Therapeutics 3
 Journal of Neurophysiology 3
 Journal of Neuroscience Research 3
Continued
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Journal n 
 Molecular Cancer Therapeutics 3
 Journal of Neurochemistry 2
 Frontiers in Neural Circuits 2
 Current Biology 2
 Journal of Clinical Investigation 2
 Journal of Cellular Physiology 2
 Carcinogenesis 2
 Journal of Cellular Biochemistry 2
 Journal of Bone and Mineral Research 2
 Vaccine 2
 Infection and Immunity 2
 Immunology 2
 Hippocampus 2
 Experimental Cell Research 2
 Genes & Development 2
 FEBS Journal 2
 Journal of Cell Biology 2
 Neurobiology of Disease 2
 Molecular Pharmacology 2
 Biomaterials 2
 Science 2
 Molecular and Cellular Endocrinology 2
 Arteriosclerosis, Thrombosis, and Vascular 
Biology 2
 Cancer Cell 2
 Molecular Brain 2
 Molecular Biology of the Cell 2
 Cardiovascular Research 2
 Biomedical Materials 1
 eLife 1
 Autophagy 1
 Disease Models & Mechanism 1
 Emerging Infectious Diseases  1
 Endocrine-Related Cancer 1
 Diabetologia 1
 Eukaryotic Cell 1
 Biochemistry 1
 Biochemical Journal 1
 BioMedical Engineering Online 1
 Experimental Hematology 1
 Food and Chemical Toxicology 1
 Acta Physiologica (Oxford) 1
 FEBS Letters 1
 American Journal of Physiology-Heart and 
Circulatory Physiology
1
Table 1 Continued 
Continued
Journal n 
 American Journal of Sports Medicine 1
 Aquatic Toxicology 1
 Annals of Neurology 1
 European Journal of Medicinal Chemistry 1
 Antimicrobial Agents and Chemotherapy 1
 European Urology 1
 European Journal of Pharmacology 1
 Developmental Cell 1
 European Journal of Neuroscience 1
 Diabetes 1
 Animal Genetics 1
 Cellular Signalling 1
 Cancer Prevention Research (Phila) 1
 Cancer Research 1
 International Journal of Developmental 
Biology 1
 Cancer Immunology, Immunotherapy 1
 Cell Cycle 1
 Cell Growth & Differentiation 1
 Cell Host & Microbe 1
 Brain Structure and Function 1
 Brain Stimulation 1
 Brain Research 1
 British Journal of Pharmacology 1
 Cell Metabolism 1
 Cellular Microbiology 1
 Biophysical Journal 1
 BMC Immunology 1
 Development, Growth & Differentiation 1
 Developmental Dynamics 1
 Cancer Letters 1
 Biotechnology and Bioengineering 1
 BMC Bioinformatics 1
 British Journal of Haematology 1
 BMC Cell Biology 1
 British Journal of Anaesthesia 1
 Cytotherapy 1
 BMC Physiology 1
 Bone 1
 Clinical Cancer Research 1
 Circulation Journal 1
 Bioorganic & Medicinal Chemistry Letters 1
 BMC Cancer 1
 Molecular Neurodegeneration 1
 Mediators of Inflammation 1
Table 1 Continued 
Continued
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group nor that the assessment was not performed blinded to 
experimental group.
Where a manuscript described both in vivo and in vitro 
research, the series of questions was completed for each. 
Where there was more than one in vitro experiment 
or more than one in vivo experiment, the question was 
considered in aggregate; that is, all in vitro experiments 
Journal n 
 Neuroscience 1
 Neuropharmacology 1
 Neuro-Oncology 1
 Neoplasia 1
 Mutagenesis 1
 Molecular Vision 1
 Nucleic Acids Research 1
 Molecular Pain 1
 Pharmacology Research & Perspectives 1
 Molecular Immunology 1
 Molecular Human Reproduction 1
 Molecular Ecology 1
 Molecular and Cellular Neuroscience 1
 Molecular and Cellular Biology 1
 Molecular BioSystems 1
 Microbiology 1
 International Immunopharmacology 1
 Molecular Reproduction and Development 1
 Reproductive Biology and Endocrinology 1
 Toxicological Sciences 1
 Tissue Engineering Part C: Methods 1
 Tissue Engineering Part A 1
 Stem Cells 1
 Stem Cell Research 1
 Stem Cell Reports 1
 Science Translational Medicine 1
 Nuclear Medicine and Biology 1
 RNA 1
 Journal of Zoo and Wildlife Medicine 1
 Proteomics 1
 Proteins 1
 Prostate 1
 Prostaglandins, Leukotrienes and Essential 
Fatty Acids 1
 Proceedings of the Royal Society B: 
Biological Sciences 1
 PLoS Pathogens 1
 PLoS Biology 1
 Physics in Medicine & Biology 1
 Science Signaling 1
 Hepatology 1
 Microbial Pathogenesis 1
 Investigative Ophthalmology & Visual Science 1
 International Journal of Hematology 1
 International Journal of Genomics 1
Table 1 Continued 
Continued
Journal n 
 International Journal of Cancer 1
 Acta Biomaterialia 1
 Infection, Genetics and Evolution 1
 Journal of Allergy and Clinical Immunology 1
 Human Mutation 1
 Journal of Applied Toxicology 1
 Hearing Research 1
 Gynecologic Oncology 1
 Gut Microbes 1
 Gut 1
 Glia 1
 Genetics & Epigenetics 1
 Genes to Cells 1
 Gene 1
 Hypertension 1
 Journal of Experimental Medicine 1
 Journal of Surgical Research 1
 Journal of Reproductive Immunology 1
 Journal of Photochemistry and Photobiology 
B 1
 Journal of Pharmaceutical and Biomedical 
Analysis 1
 Journal of Pathology 1
 Journal of Neural Engineering 1
 Journal of Infectious Diseases 1
 IUBMB Life 1
 Journal of General Physiology 1
 G3 (Bethesda) 1
 Journal of Dental Research 1
 Journal of Controlled Release 1
 Journal of Comparative Neurology 1
 Journal of Chromatography B Analytical 
Technologies in the Biomedical and Life 
Sciences 1
 Journal of Bioscience and Bioengineering 1
 Journal of Biomedical Optics 1
 Journal of Biomedicine and Biotechnology 1
 Journal of Autoimmunity 1
 Journal of Hepatology 1
Table 1 Continued 
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had to meet the requirements of the checklist item for 
the article to be considered compliant in reporting of 
in vitro experiments, and all in vivo experiments had 
to meet the requirements of the checklist item for the 
article to be considered compliant in reporting of in vivo 
experiments. Where an item was considered only partially 
compliant, we considered this, for the purposes of anal-
ysis, to be non-compliant. Where a particular checklist 
item was not relevant for a given manuscript (randomi-
sation in observational studies, or power calculations in 
explicitly exploratory studies12), this item was considered 
‘not applicable’ and the manuscript was not included in 
the analysis of that item.
Five researchers experienced in systematic review and 
risk of bias annotation scored a set of 10 articles using 
our series of questions. Disagreements were resolved by 
group discussion, to arrive at a set of ‘Gold standard’ 
answers for these 10 articles. We also used this experience 
to write a training guide for outcome assessors. We then 
used social media platforms and mailing lists to recruit 
outcome assessors. We sought to recruit individuals with 
a background in medicine or biomedicine at a grad-
uate or undergraduate level who we believed should 
have experience in the critical appraisal of published 
materials. However, we also recruited two senior school 
students on Nuffield Research Placements in our group. 
After outcome assessors had reviewed the training mate-
rials, they were invited to score articles from the ‘Gold 
standard’ pool, presented in random order, until their 
concordance with the gold standard responses was 80% 
overall, and was 100% for the components of the primary 
outcome measure, for three successive articles. At this 
point we considered them to be trained. The 10 training 
data sets, with their ‘gold standard’ adjudications, were 
included in the analysis (using the gold standard adjudi-
cations). Because of the range of expertise available, we 
ensured that each manuscript was reviewed by at least one 
assessor highly experienced in systematic review and crit-
ical appraisal. The training platform remains available for 
continuing professional development at https:// ecrf1. 
clinicaltrials. ed. ac. uk/ npqip/.
PDF files of included articles were uploaded to the study 
website. Trained assessors were presented with articles for 
scoring in random order. Each manuscript was scored by 
two individuals, one with experience in systematic review 
and risks of bias annotation and one other. Disagreements 
between assessors were reconciled by a third, experienced 
individual who was not one of the original reviewers, who 
could see the responses previously given but not who 
were the initial reviewers. Each item for each manuscript 
was therefore scored by two (if there was agreement) or 
three (if there was disagreement) reviewers, except for 
the 10 manuscripts which served as the gold standard, 
which had been scored by five experienced assessors. We 
had intended to monitor outcome assessment after 10% 
of manuscripts had been scored and reconciled, but the 
reconciliation process lagged behind the outcome assess-
ment, and this was not done.
statistical analysis plan
Given our focus on the reporting of measures to reduce 
the risks of bias, we took as our primary outcome measure 
a composite measure of the proportion of articles meeting 
the relevant measures identified by Landis et al in 2012 
as being most important for transparency in reporting in 
vivo research. These are covered by items 2, 3 4 and 5 of 
the checklist and relate to the reporting of randomisa-
tion, of the blinded assessment of outcome, of sample size 
calculations, and of whether the manuscript described 
whether samples or animals were excluded from analysis. 
Importantly, checklist compliance did not require, for 
example, that the study was randomised, but rather that 
the authors stated whether or not it was randomised. The 
evaluation principle was to determine if someone with 
reasonable domain knowledge could understand the 
parameters of experimental design sufficiently to inform 
interpretation. It has been argued that these measures 
might not be as relevant for exploratory studies, and for 
these we recorded the item as ‘not relevant’. We defined 
exploratory studies as those where hypothesis testing 
inferential statistical analyses were not reported. Where 
an item was not relevant for a publication (for instance 
with studies using transgenic animals where group allo-
cation had been achieved by Mendelian randomisation), 
we considered compliance as meeting all of the relevant 
criteria. Where a publication described both in vivo and 
in vitro experiments, we analysed each type of experi-
ment separately.
Our primary outcome was the proportion of articles 
describing in vivo experiments published by NPG after 
May 2013 that meet all of the relevant Landis 4 criteria. 
This is described in the statistical analysis plan deposited 
on the Open Science Framework ( osf. io/ hc7fk) on 7 June 
2017 prior to database lock and before we had derived 
any outcome information. Following discussion with the 
NPG editorial team, we also set out in the protocol11 
some predefined ‘editorially significant changes’—either 
reaching compliance of 80% or an increase of 15% in 
compliance.
We used the two-sample proportion test ( prop. test) in 
R without the Yates continuity correction and two-sided 
hypothesis testing to be sensitive to the possibility that 
performance might have declined rather than improved. 
The secondary outcomes were (1) whether the propor-
tion of articles describing in vivo experiments published 
by NPG after May 2013 which met all four of the Landis 
4 criteria was 80% or higher (the original primary 
outcome; Wald test,  wald. ptheor. test, RVAideMem-
oire in R); (2) the change in the proportion of articles 
describing in vitro experiments published by NPG before 
and after May 2013 which met all four of the Landis 4 
criteria (two-sample proportion test as above); and (3) 
the change in the proportion of manuscripts meeting 
the criteria for adequate reporting of statistical analysis 
details, individual Landis criteria, descriptions of animals, 
reagents and their availability, biological sequences or 
structures, computer code deposition, and items relating 
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to the involvement of human subjects or materials in 
included studies. For the matching articles from non-NPG 
journals, the secondary outcomes were (1) the change in 
the proportion of articles describing in vivo experiments 
published before and after May 2013 which met all of 
the Landis 4 criteria (two-sample proportion test); (2) 
whether the proportion of articles describing in vivo 
experiments published after May 2013 which met all four 
of the Landis 4 criteria was 80% or higher (Wald test); (3) 
the change in the proportion of articles describing in 
vitro experiments published before and after May 2013 
which met all four of the Landis 4 criteria (two-sample 
proportion test); and (4) the change in the proportion 
of manuscripts meeting the criteria for reporting of statis-
tical analysis details, individual Landis criteria, descrip-
tions of animals, reagents and their availability, biological 
sequences or structures, computer code deposition, and 
items relating to the involvement of human subjects or 
materials in included studies. For each of these outcomes, 
we compared the changes observed in NPG articles with 
that observed in non-NPG articles. For each secondary 
analysis we used the Holm-Bonferroni correction using 
the p.adjust option for  prop. test in R to account for the 
number of comparisons drawn, as described in appendix 
B of the data analysis plan. We also used interrupted 
time series analysis for each checklist item to distinguish 
a discrete ‘shift’ in performance from an upward ‘drift’, 
as described in the data analysis plan. Several tertiary 
outcomes are described in the study protocol and statis-
tical analysis plan and are reported in the supplementary 
material.
Power calculations
Power calculations were performed in STATA (Version 
13.0) prior to commencement of the study. For the 
primary outcome measure, we approximated required 
sample sizes using power calculations for a one-sided 
two-sample χ2 test in STATA seeking a significance level 
of p<0.01 and with varying estimates of compliance with 
the Landis 4 criteria in the preintervention group. With 
200 articles in each group, we had 80% power to detect 
an increase from 10% to 21%, or from 20% to 34%, or 
from 30% to 45%, or from 40% to 56%, or from 50% to 
66%. We wanted to detect an absolute difference of 10% 
or more and thought that compliance with the Landis 4 
criteria in the preintervention group would be around 
10%, so we thought that having 200 studies in each group 
would be enough.
For the primary outcome measure proposed in the 
original study protocol (that compliance with the Landis 
4 criteria in the postintervention group reached 80%), 
200 studies in each group would be sufficient to reject 
Figure 1 Articles initially included, and reasons for exclusion, and type of experiments described. NPG, Nature 
Publishing Group.
 o
n
 27 February 2019 by guest. Protected by copyright.
http://openscience.bmj.com/
BM
J O
pen Science: first published as 10.1136/bmjos-2017-000035 on 1 February 2019. Downloaded from 
8  The NPQIP Collaborative group. BMJ Open Science 2019;3:e000035. doi:10.1136/bmjos-2017-000035
Open access 
the alternative hypothesis if the observed compliance 
was 72% or lower, and again we considered this to be 
sufficient.
For individual checklist items, after correcting for 
multiple comparisons, statistical power again depends 
on the level of reporting in the preintervention group. 
Where this was between 15% and 85%, with 200 studies 
per group, we would have 80% power to detect an abso-
lute increase of 15% in the reporting of each item. We 
considered this to be the minimal increase that would 
represent an important improvement in reporting. The 
power calculations are described in greater detail in the 
study protocol.11
results
Eight hundred and ninety-six articles were identified and 
uploaded for outcome ascertainment, 448 in each cohort. 
Table 2 Distribution of country of origin of the senior author in each cohort
Country
NPG (before) NPG (after) Non-NPG (before) Non-NPG (after) Total
n % n % n % n % n %
USA 153 69.9 159 71.0 77 39.7 103 42.6 492 56.0
Germany 21 9.6 17 7.6 18 9.3 18 7.4 74 8.4
UK 14 6.4 16 7.1 5 2.6 19 7.9 54 6.1
China 5 2.3 4 1.8 15 7.7 20 8.3 44 5.0
Japan 3 1.4 3 1.3 25 12.9 10 4.1 41 4.7
Canada 4 1.8 3 1.3 7 3.6 13 5.4 27 3.1
France 5 2.3 6 2.7 7 3.6 5 2.1 23 2.6
Italy 3 1.4 3 1.3 2 1.0 7 2.9 15 1.7
South Korea 7 3.6 8 3.3 15 1.7
Switzerland 3 1.4 1 0.4 4 2.1 3 1.2 11 1.3
Australia 1 0.5 1 0.4 5 2.6 2 0.8 9 1.0
Spain 1 0.5 1 0.4 1 0.5 6 2.5 9 1.0
Austria 3 1.4 3 1.3 2 0.8 8 0.9
Sweden 6 3.1 2 0.8 8 0.9
The Netherlands 1 0.5 3 1.5 2 0.8 6 0.7
Taiwan 1 0.4 2 1.0 3 1.2 6 0.7
Denmark 1 0.5 2 0.9 1 0.5 1 0.4 5 0.6
India 1 0.5 1 0.4 3 1.2 5 0.6
Belgium 2 1.0 1 0.4 3 0.3
New Zealand 2 1.0 1 0.4 3 0.3
Finland 1 0.5 1 0.4 2 0.2
Hungary 2 0.8 2 0.2
Israel 1 0.5 1 0.4 2 0.2
Portugal 1 0.5 1 0.4 2 0.2
Singapore 1 0.4 1 0.4 2 0.2
Argentina 1 0.4 1 0.1
Bangladesh 1 0.5 1 0.1
Brazil 1 0.4 1 0.1
Bulgaria 1 0.4 1 0.1
Cameroon 1 0.4 1 0.1
Chile 1 0.5 1 0.1
Greece 1 0.4 1 0.1
Mexico 1 0.4 1 0.1
Norway 1 0.4 1 0.1
Poland 1 0.4 1 0.1
Russia 1 0.4 1 0.1
Total 219 224 194 242 879
NPG, Nature Publishing Group. 
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Two non-NPG articles were excluded because they did not 
meet the inclusion criteria, and we identified four NPG 
and nine non-NPG articles which had been included 
more than once. Four hundred and forty-four NPG arti-
cles and 437 non-NPG articles underwent outcome assess-
ment. One NPG publication and one non-NPG publica-
tion were adjudged at the time of outcome assessment to 
report neither in vivo nor in vitro research, and so were 
excluded. The analysis is therefore based on 443 NPG 
articles (219 before and 224 after 1 May 2013) and 436 
non-NPG articles (194 before and 242 after 1 May 2013) 
(figure 1). The difference in numbers for NPG and 
non-NPG before and after 1 May 2013 is because some 
of the NPG ‘before’ articles matched best with articles 
in other journals published in the few months following 
May 2013. Specifically, 26 NPG preintervention articles 
were matched with other papers published an average of 
3.2 months after May 2013 (maximum of 8 months), and 
6 NPG postintervention articles were matched with other 
papers published 1, 2, 9, 11, 12 and 215 months before 
May 2013. Overall, 43% of matched pairs had dates of 
publication within 1 month, 54% within 2 months, 64% 
within 3 months and 81% within 6 months of each other 
(range −11 to +22 months). Two hundred and thirty-nine 
articles described only in vivo research, 133 described only 
in vitro research and 507 described both. Four hundred 
and ninety-four papers were completely matched for in 
vivo and in vitro status, 276 were partially matched (one 
member of matched pair reporting in vivo and in vitro 
research, the other reporting only in vitro or only in vivo 
research) and 36 were mismatched (one reporting only in 
vivo research, the other reporting only in vitro research). 
The source journals are given in table 1; in total 198 
different titles contributed matching articles (median of 
1 article per source journal, range 1–47). The PMIDs of 
included articles are listed in the data supplement.
We had intended to perform subgroup analyses in 
groups defined by country of origin, categorisation of 
research, and whether the study was predominantly 
in silico, in vitro, in vivo or involved human subjects. 
However, because for some countries the number of 
included manuscripts was low, the categorisation of 
research was not available for all manuscripts in the 
matching non-NPG group (except by inference from the 
matched NPG papers), the number of predominantly in 
silico and predominantly human studies was low, and we 
were not confident that we could operationalise a judge-
ment as to whether a paper was predominantly in vivo 
or in vitro, we elected not to pursue these analyses. The 
country of origin for papers in each cohort is shown in 
table 2.
Two hundred and five individuals registered with the 
project, of whom 109 started at least one training manu-
script, 38 completed their training and 35 assessed at 
least one manuscript. Of these 35, 12 individuals also 
reconciled conflicting outcome assessments, and the web 
interface was programmed to ensure that they were not 
offered for reconciliation articles that they had previously T
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adjudicated. Including reconciliation, the median 
number of articles scored was 13 (range 1–441). The 
agreement between outcome assessors ranged from being 
no better than chance at 50% (in vivo studies; implemen-
tation of statistical methods and measures: ‘Is the variance 
similar (difference less than two-fold) between the groups 
that are being statistically compared?’) to 98% (in vivo 
studies; ‘Does the study report the species?’). The median 
agreement was 82% (IQR 68%–89%). Two articles were 
identified during manuscript preparation as having been 
incorrectly recorded at data lock as reporting both in vivo 
and in vitro research, where in fact they only reported 
in vitro research, and one article had been incorrectly 
recorded as reporting both in vivo and in vitro research, 
where in fact it only reported in vivo research.
reporting of the landis 4 items
The proportion of NPG in vivo studies reaching full 
compliance with the Landis 4 criteria increased from 0% 
(0/203) to 16.4% (31/189) (Χ²=36.1, df=1, p=1.8×10−9), 
but remained significantly lower than the target of 80% 
(95% CI 11.6% to 22.6%, Wald test versus 80% z=−15.4, 
p=2.2×10−16). In the tables the denominator number 
of studies (‘N’) differs according to whether that crite-
rion is relevant to the work presented; for instance, in 
transgenic studies randomisation may not be appro-
priate (tables 3–5).
Because the number of manuscripts with a country of 
origin other than the USA and the number of studies which 
were predominantly in silico (we used studies which used 
computer code as a surrogate for the upper extent of this) 
were small, we did not analyse these further. There were 
no differences in compliance with the primary outcome 
measure dependent on whether the study included human 
research, or whether they included both in vivo and in vitro 
research or in vivo research alone.
Randomisation
The preferred standard is that the manuscript describes 
which method of randomisation was used to determine 
how samples or animals were allocated to experimental 
groups, although articles were also compliant if they 
included a statement about randomisation even if no 
randomisation was used. The proportion of NPG in vivo 
studies reporting the method of randomisation was 1.8% 
before and 11.2% after (χ²=12.4, df=1, adjusted p=0.054). 
Of the remainder, the proportion of studies mentioning 
randomisation increased from 8.3% to 64.2% (χ²=110.2, 
df=1, adjusted p=3.2×10−14); overall, 68% of studies 
discussed randomisation in some way and so were judged 
compliant. Figure 2A shows change in the proportion of 
studies meeting these criteria before and after the change 
in editorial policy.
Blinding
The preferred standard is that the manuscript describes 
whether the investigator was blinded to the group alloca-
tion during the experiment and/or when assessing the T
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outcome, although articles were also compliant if they 
included a statement about blinding even if no blinding 
was done. The proportion of NPG in vivo studies reporting 
blinding during group allocation or outcome assessment 
or both increased from 4% to 22.8% (Χ²=29.6, df=1, 
adjusted p=7.6×10−6). Of the remainder, the proportion I
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Figure 2 Compliance with each Landis criteria for in vivo 
experiments for NPG (top two panels of each quartet) and 
non-NPG articles (lower two panels) before and after 1 
May 2013. (A) Randomisation; (B) blinding; (C) sample size 
calculation; and (D) reporting of exclusions. For A–C, black 
represents studies where compliance was achieved by 
reporting that the measure was taken; green that compliance 
was achieved by describing that the measure was not 
taken; and white that compliance was not achieved. For D, 
black represents studies where exclusions were reported 
and white that exclusions were not reported. NPG, Nature 
Publishing Group.
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of studies mentioning blinding increased from 1.6% to 
55.3% (Χ²=120.1, df=1, adjusted p<3.2×10−14); overall, 
63% of studies discussed blinding in some way and so 
were judged compliant. Figure 2B shows change in the 
proportion of studies meeting these criteria before and 
after the change in editorial policy.
Exclusions
The proportion of studies reporting animals excluded 
from analysis increased from 13.9% to 30.7% (Χ²=16.1, 
df=1, adjusted p=0.008). Figure 2C shows change in the 
proportion of studies meeting these criteria before and 
after the change in editorial policy.
Sample size calculations
The preferred standard is that the manuscript describes 
how the sample size was chosen to ensure adequate power 
to detect a prespecified effect size, although articles 
were also compliant if they included a statement about 
sample size estimate even if no statistical methods were 
used. The proportion of studies reporting an a priori 
sample size calculation increased from 2.0% to 14.8% 
(Χ²=20.5, df=1, adjusted p=0.0008). Of the remainder, 
the proportion of studies mentioning sample size calcu-
lations increased from 1.6% to 58.4% (Χ²=140.7, df=1, 
adjusted p<3.2×10−14); overall, 64% of studies discussed 
sample size calculations in some way and so were judged 
compliant. Figure 2D shows change in the proportion of 
studies meeting these criteria before and after the change 
in editorial policy.
For NPG in vitro studies, the proportion reaching full 
compliance with the Landis 4 criteria was 0% (0/159) 
before and 3.3% (6/176) after (Χ²=6.8, df=1, Holm-Bon-
ferroni adjusted p=1.00). The proportion of studies 
reporting randomisation was 0% before and 2.9% after 
(Χ²=4.4, df=1, adjusted p=1.00). The proportion of 
studies mentioning randomisation even where it was 
not reported increased from 0% to 15.6% (Χ²=25.3, 
df=1, p=6.9×10−5). The proportion of studies reporting 
blinding during group allocation or outcome assessment 
or both was 3.9% before and 8.9% after (Χ²=3.467, df=1, 
p=1.00). The proportion of studies mentioning blinding 
even where it was not reported increased from 0.7% 
to 15.9% (Χ²=23.0, df=1, p=0.0002). The proportion 
of studies reporting exclusions from analysis was 8.2% 
before and 15.9% after (Χ²=4.73, df=1, p=1.00). The 
proportion of studies reporting an a priori sample size 
calculation was 1.3% before and 7.9% after (Χ²=8.7106, 
df=1, p=1.00). The proportion of studies mentioning 
sample size even where a sample size calculation was not 
reported increased from 3.3% to 28.5% (Χ²=36.9, df=1, 
p=1.8×10−7).
The proportion of matching (non-NPG) in vivo studies 
reaching full compliance with the Landis 4 criteria was 
1% before and 1% after (Χ²=0.01, df=1, adjusted p=1.00), 
and for in vitro studies the proportion of non-NPG studies 
reaching full compliance with the Landis 4 criteria was 
0% before and 1% after (Χ²=0.8, df=1, adjusted p=1.00). 
There was no significant change in reporting of any of the 
individual Landis 4 criteria for either in vivo or in vitro 
research.
statistical reporting
For in vivo studies reported in NPG articles, there were 
significant improvements in the reporting of exact 
numbers (from 46% to 69%, Χ²=22.07, df=1, adjusted 
p=0.0004), of whether t-tests were defined as one-sided 
or two-sided (from 46% to 71%, Χ²=17.80, df=1, adjusted 
p=0.003), and whether the assumptions of the test 
had been checked (from 9% to 27%, Χ²=18.58, df=1, 
adjusted p=0.002). For in vitro experiments described 
in NPG articles, there were significant improvements in 
the reporting of the exact numbers (from 32% to 70%, 
Χ²=12.60, df=1, adjusted p=0.05), of whether data repre-
sented technical or biological replicates (from 57% to 
75%, Χ²=13.29, df=1, adjusted p=0.035), and whether 
t-tests were defined as one-sided or two-sided (from 47% 
to 72%, Χ²=16.18, df=1, adjusted p=0.008). For in vivo 
and in vitro studies described in non-NPG articles, there 
was no significant change in any of the items relating to 
statistical reporting (table 6).
Other checklist items
For reporting of details of animals used, reporting of 
animal species and strain was high even before the change 
in editorial policy. There was no significant change in 
reporting any of these items in NPG and non-NPG arti-
cles, or in the reporting of details of antibodies used. For 
in vitro research, there was an increase in the proportion 
of studies in NPG articles reporting recent mycoplasma 
testing of the cell lines used (from 1% to 26%, Χ²=26.60, 
df=1, adjusted p=4×10−5) but not for non-NPG articles 
(1% before, 1% after). For reporting and availability of 
accession data (eg, DNA or protein sequence deposition) 
and computer code, there were no significant changes for 
either NPG or non-NPG articles. Finally, there were no 
significant changes in the reporting of items relating to 
human subjects or the use of human materials, but for 
most items the number of articles for which these were 
relevant was very low indeed (table 7).
In our protocol we defined the smallest effect size of 
editorial interest following the intervention at NPG as 
either achievement of compliance of 80% (transparency 
in figures and statistical description, data deposition, 
and for in vivo research description of animals used and 
aggregate and individual compliance Landis 4 items) or 
an absolute improvement of 15% in the reporting of a 
checklist item (all other items). Table 8 shows, for each 
item, the 95% CI of both the compliance achieved and 
the change in compliance before and after checklist 
implementation. Using this approach, we were able reli-
ably to exclude an improvement of 15% or more in NPG 
manuscripts for full and individual item Landis compli-
ance for in vitro research; reporting full statistics for 
both in vivo and in vitro research; correction for multiple 
testing, and reporting measures of variation, and whether 
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Table 8 95% CIs for the observed compliance (columns 1–4) and change in compliance (columns 5 and 6)
Item
95% CI for compliance
95% CI for change in 
compliance
NPG before NPG after
Non-NPG 
before
Non-NPG 
after NPG Non-NPG
In vivo: full Landis – 11.7 to 22.2 0.0 to 4.2 0.0 to 3.7 11.1 to 21.6 −1.6 to 1.5
In vitro: full Landis – 1.5 to 7.1 – 0 to 4.2 0.7 to 5.9 −0.6 to 1.8
In vivo: randomisation 6.3 to 15.5 60.9 to 74.8 3.0 to 11.5 7.2 to 17.7 49.1 to 65.7 −1.3 to 12.3
In vivo: blinding 3.1 to 9.8 55.3 to 69.2 0.6 to 5.6 3.3 to 10.4 48.7 to 64.0 −0.2 to 8.6
In vivo: exclusions reported 9.7 to 19.3 24.5 to 37.6 6.1 to 15.3 10.1 to 20.0 8.6 to 24.8 −2.3 to 11.3
In vivo: sample size calculation 1.7 to 7.3 57.1 to 70.9 0.0 to 4.4 1.8 to 7.7 52.7 to 67.6 −0.3 to 7.0
In vitro: randomisation – 12.9 to 24.4 0.1 to 5.5 – 12.3 to 24.3 −4.4 to 1.8
In vitro: blinding 2.2 to 9.2 17.2 to 29.6 0.7 to 6.9 2.0 to 8.5 11.2 to 25.5 −2.8 to 6.4
In vitro: exclusions reported 4.8 to 13.6 11.3 to 22.0 2.5 to 10.6 4.6 to 12.9 0.1 to 14.6 −3.6 to 8.2
In vitro: sample size calculation 2.2 to 9.2 27.8 to 41.8 – 2.0 to 8.5 22.0 to 37.6 0.6 to 8.4
In vivo: exact n 39.8 to 52.7 62.4 to 75.5 38.8 to 54.0 40.1 to 54.2 13.8 to 32.6 −9.6 to 11.0
In vivo: technical or biological 
replicates
61.4 to 74.2 74.0 to 85.4 48.4 to 63.5 47.1 to 61.2 3.4 to 20.6 −12.1 to 8.5
In vivo: number of times 
replicated
17.3 to 28.9 30.5 to 44.4 15.7 to 28.3 14.1 to 25.4 5.4 to 23.5 −10.7 to 6.2
In vivo: test described if 
uncommon?
37.5 to 64.3 48.3 to 71.7 41.1 to 71.9 42.4 to 69.9 −8.4 to 26.4 −19.7 to 18.9
In vivo: t-test defined as one-
sided or two-sided?
37.6 to 54.4 62.9 to 77.7 21.8 to 39.7 36.8 to 55.3 13.4 to 35.6 2.7 to 28.2
In vivo: correction for 
multiplicity
45.2 to 63.1 47.6 to 65.1 46.6 to 65.8 53.7 to 71.0 −10.2 to 14.6 −6.6 to 19.0
In vivo: reporting full statistics 17.6 to 30.4 15.6 to 27.8 10.3 to 22.5 8.4 to 19.0 −6.6 to 10.6 −10.9 to 5.4
In vivo: reporting of average 67.7 to 80.4 79.1 to 90.4 67.2 to 81.2 64.8 to 78.3 3.0 to 19.5 −12.4 to 7.0
In vivo: definition of error bars 82.2 to 91.9 87.1 to 95.4 74.8 to 87.4 71.2 to 83.8 −0.12 to 10.8 −12.5 to 5.3
In vivo: testing of assumptions 5.4 to 14.0 20.5 to 33.9 5.2 to 15.1 7.4 to 17.6 9.8 to 25.9 −4.7 to 9.6
In vivo: reporting measures of 
variation
71.6 to 83.5 74.2 to 86.0 73.4 to 86.9 66.6 to 80.3 −5.8 to 11.0 −16.1 to 2.4
In vivo: variation less than 
twofold
14.8 to 37.8 25.1 to 48.8 14.5 to 38.4 22.3 to 48.0 −5.4 to 27.3 −8.3 to 26.5
In vitro: exact n 25.4 to 40.0 44.1 to 58.6 29.1 to 45.4 19.9 to 33.3 8.6 to 29.0 −21.2 to −0.2
In vitro: technical or biological 
replicates
48.8 to 64.1 68.5 to 81.0 31.2 to 47.6 35.1 to 50.1 8.6 to 28.3 −7.9 to 14.3
In vitro: number of times 
replicated
31.9 to 47.1 39.8 to 54.2 28.6 to 44.9 28.4 to 43.0 −2.8 to 18.0 −11.9 to 9.8
In vitro: test described if 
uncommon?
39.7 to 69.0 49.0 to 73.6 29.5 to 58.0 22.6 to 51.9 −11.7 to 26.0 −26.9 to 13.4
In vitro: t-test defined as one-
sided or two-sided?
37.6 to 56.2 64.0 to 79.3 23.6 to 43.8 24.7 to 44.1 13.1 to 37.0 −13.2 to 14.6
In vitro: correction for 
multiplicity
37.6 to 56.7 42.6 to 60.8 36.7 to 57.6 44.2 to 63.5 −8.5 to 17.7 −7.4 to 20.9
In vitro: reporting full statistics 12.4 to 25.1 11.8 to 23.5 8.9 to 22.0 9.2 to 21.0 −9.7 to 7.6 −9.3 to 8.5
In vitro: reporting of average 74.5 to 87.3 81.4 to 91.8 62.9 to 78.6 67.4 to 81.3 −2.4 to 13.8 −6.8 to 14.1
In vitro: definition of error bars 85.6 to 94.9 89.8 to 97.1 72.3 to 86.4 74.4 to 87.0 −2.6 to 9.4 −8.2 to 10.8
In vitro: testing of assumptions 5.5 to 15.4 16.1 to 29.1 3.1 to 12.8 3.6 to 12.5 4.2 to 20.7 −6.6 to 6.9
In vitro: reporting measures of 
variation
67.6 to 81.4 74.8 to 86.7 62.7 to 78.4 62.1 to 76.9 −2.8 to 15.5 −11.8 to 9.7
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Item
95% CI for compliance
95% CI for change in 
compliance
NPG before NPG after
Non-NPG 
before
Non-NPG 
after NPG Non-NPG
In vitro: variation less than 
twofold
9.8 to 31.7 17.2 to 40.4 15.4 to 40.5 24.9 to 52.6 −7.5 to 24.3 −7.3 to 30.0
Animals: was the species 
reported?
97.7 to 100 97.5 to 100 95.8 to 99.9 96.3 to 99.9 −2.0 to 1.9 −2.4 to 2.9
Animals: was the strain 
reported?
87.5 to 95.1 91.8 to 97.9 85.4 to 94.4 88.5 to 96.0 −1.2 to 8.6 −3.5 to 8.4
Animals: was the sex reported? 29.3 to 47.8 45.0 to 59.3 29.6 to 44.4 30.0 to 43.8 6.4 to 26.0 −10.2 to 10.0
Animals: was exact age or 
weight given?
11.0 to 20.9 16.5 to 28.3 19.0 to 32.2 15.4 to 27.0 −1.2 to 14.3 −13.2 to 4.4
Animals: was ethical approval 
reported?
52.7 to 66.5 60.1 to 74.4 52.3 to 67.8 61.2 to 74.7 −1.6 to 17.7 −2.2 to 18.3
Animals: ethical guidelines 
reported?
67.9 to 80.0 79.1 to 89.6 65.9 to 79.9 68.9 to 81.4 2.6 to 18.6 −7.1 to 11.6
Reagents: in vivo antibodies 54.4 to 70.2 64.5 to 79.4 25.1 to 42.1 37.2 to 54.4 −1.1 to 20.6 0.2 to 24.4
Reagents: in vitro antibodies 51.2 to 68.2 67.6 to 81.7 20.1 to 37.2 32.2 to 49.2 4.1 to 26.2 0.2 to 24.2
Reagents: total antibodies 55.4 to 67.1 68.5 to 78.8 24.8 to 37.0 37.1 to 49.3 4.7 to 20.2 3.8 to 20.9
Cell line: source 40.4 to 59.6 61.9 to 77.1 52.3 to 72.7 46.5 to 64.8 7.6 to 31.9 −20.5 to 6.7
Cell line: recent authentication? 0.2 to 7.1 3.8 to 13.2 2.0 to 13.2 0.2 to 7.0 0.3 to 12.0 −11.8 to 1.4
Cell line: recent mycoplasma 
testing?
0.2 to 7.0 19.1 to 34.3 0.2 to 8.6 0.2 to 7.0 16.7 to 33.2 −6.0 to 4.4
Accession: DNA/protein 36.9 to 61.5 38.0 to 62.0 27.8 to 68.2 28.8 to 56.9 −16.2 to 17.8 −29.4 to 18.7
Accession: macromolecular 0.0 to 60.4 20.2 to 88.2 0.0 to 80.2 21.9 to 98.7 −1.4 to 84.1 −4.6 to 95.4
Accession: crystallography 30.2 to 94.9 7.3 to 60.7 9.4 to 90.5 0.0 to 94.5 −71.0 to 1.9 −39.1 to 90.6
Accession: microarray 21.9 to 53.7 39.5 to 70.1 24.1 to 70.7 42.9 to 84.2 −4.2 to 39.2 −12.6 to 47.7
Accession: other 7.2 to 67.3 24.0 to 67.0 10.5 to 70.1 24.1 to 94.0 −24.8 to 45.7 −9.4 to 75.4
Computer code: with paper? 7.1 to 49.4 9.0 to 41.3 0.0 to 53.7 3.6 to 42.7 −29.2 to 23.4 −30.4 to 39.9
Computer code: in public 
domain?
9.0 to 58.6 9.0 to 41.3 0.0 to 53.7 3.9 to 45.1 −37.9 to 19.9 −29.4 to 42.2
Computer code: was that code 
accessible?
12.5 to 98.2 30.2 to 94.9 0.0 to 94.5 15.0 to 85.0 −40.0 to 55.0 −36.7 to 85.0
Computer code: did the code 
function ?
12.5 to 98.2 19.8 to 100 – – −37.8 to 79.2 – 
Computer code: say where you 
could get code?
0.0 to 37.1 0.3 to 32.3 7.2 to 83.0 0.0 to 34.4 −24.1 to 28.3 −76.9 to −0.4
Human materials reporting 
ethical approvals
67.0 to 90.4 69.9 to 90.1 36.3 to 74.8 60.4 to 87.2 −14.2 to 16.8 −3.9 to 42.2
Human materials reporting 
consent
69.0 to 91.8 71.9 to 91.4 42.2 to 79.2 47.0 to 76.8 −13.8 to 16.4 −22.1 to 24.6
Human materials consent to 
photos
12.5 to 98.2 5.4 to 100 0.0 to 80.2 −50.5 to 79.2 – 
Human materials clinical trial 
number
12.5 to 98.2 5.4 to 100 – – 
Human materials CONSORT 0.0 to 94.5 – – 
Human materials REMARK 0.0 to 94.5 0.0 to 80.2 0.0 to 94.5 – −65.8 to 79.4
Colours represent CIs falling below (red), encompassing (yellow) and exceeding (green) 80% compliance (1–4) or a 15% improvement in 
compliance. Deeper colours relate to the editorially important change criteria identified in the study protocol. Grey boxes: not applicable.
CONSORT, Consolidated Standards of Reporting Trials; NPG, Nature Publishing Group.
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the exact age or weight was given for in vivo research; 
and reporting whether the central estimate was mean or 
median, and whether cell lines used had recently been 
authenticated for in vitro research.
We were also interested in whether changes in 
reporting had occurred as a step change at the time 
of the change in editorial policy; whether there was 
an initial improvement with then a return to previous 
performance; or if there was an ongoing improvement 
in reporting. To address this question we conducted 
an interrupted time series analysis to estimate the 
rate of change before the intervention, any step 
change at the time of the intervention and the rate 
of change after the intervention. We grouped articles 
in 3-month periods starting November 2011, and for 
each quarter calculated the proportional compliance 
with the criteria in question. Because articles were 
not evenly distributed across time, the analysis is of 
substantially reduced power, but the fitted lines for 
overall compliance and for each component of the 
Landis checklist for in vivo research are shown in 
figure 3. It appears that with the exception of sample 
size calculation, there is a continuing improvement 
over time in both NPG and non-NPG articles; for 
sample size calculations, the improvement is only 
seen in NPG articles. Figure 4 shows radar charts 
of compliance for each checklist item in NPG and 
non-NPG articles before and after May 2013. Figure 5 
shows the 95% CIs for the change in performance for 
each checklist item.
Figure 3 Interrupted time series analysis for overall Landis compliance and compliance with Landis components in in vivo 
experiments reported in NPG and non-NPG articles overall, and individually for randomisation, blinding, reporting of animals 
excluded from analysis and sample size calculations. NPG, Nature Publishing Group.
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DIsCussIOn
The change in editorial policy at NPG was associated with 
improvements in reporting of randomisation, blinding, 
exclusions from analysis and sample size calculations. For 
the highly challenging primary outcome measure, full 
compliance increased from 0% to 16%. This falls short 
of the target compliance of 80%, but should be seen in 
the context, first, that only 1 of 1073 articles from 2009 to 
10 from leading UK institutions achieved this standard,1 
and second that overall compliance of 80% would require 
compliance with individual items of around 95%. Since 
these results were first communicated at the Peer Review 
Congress, in bioRxiv and in the peer review process, it 
has been suggested that the observed change is small. It 
certainly falls well short of the target of 80% compliance, 
but this needs to be seen in the context, first, of the gener-
ally poor reporting of biomedical research (as evidenced 
in the non-NPG cohort) and in the challenge involved 
with achieving compliance for a composite outcome. If 
the probabilities of compliance with each of the Landis 
4 items were independent of each other, then achieving 
80% compliance overall would require compliance with 
individual items of 94%.
Prior to the study we identified achievement of 80% 
compliance, or an absolute improvement of 15% in the 
reporting of an item, as being the minimal change which 
would represent an important effect of an editorial inter-
vention. In the NPG cohort, for 62 items the 95% CIs of 
the observed change fell below 15% for 11 items, included 
15% for 40 items and were above 15% for 5 items. For 
three items there were insufficient data to calculate 95% 
CIs, and for three items baseline performance already 
exceeded 85%.
Power calculations in primary research are often consid-
ered unfeasible, on the basis that prior to doing the study 
the effect size is not known. Our approach here—of iden-
tifying a smallest effect size of interest—is increasingly 
widely used, and has allowed us to demonstrate if any 
change observed might be as large as the smallest effect 
size of interest, is definitely that large or is definitely not 
that large. We hope that those using our findings to guide 
their own improvements will find this helpful and recom-
mend the approach for use in future studies.
It is notable that even with considerable investment in 
designing and implementing a checklist, and working 
with authors to encourage its completion, compliance 
remains so low. This stands rather in contrast to the 
belief that ‘all’ that is required to ensure transparency 
in reporting is that journals ‘insist’ that authors do the 
right thing. Securing transparency in research reports 
Figure 4 Radar plots for compliance with individual components of the NPG checklist before (red) and after (blue) 1 May 2013 
for (A) statistical reporting, in vivo research; (B) statistical reporting, in vitro research; (C) reporting of details of animals used; 
and (D) reporting of reagents used. *Adjusted p<0.05 for change between ‘before’ and ‘after’. NPG, Nature Publishing Group.
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is a complex challenge, and experience in other fields 
(MM is also clinical lead for a clinical neurology service) 
suggests such challenges require a range of complemen-
tary approaches with commitment from all stakeholders, 
might best be achieved through formal improvement 
activity, and often take multiple attempts to achieve and 
sustain change.
The checklist relates to transparency in reporting, 
and articles were judged to be compliant if they either 
reported measures to address that risk of bias or reported 
that such measures were not taken. For each of the Landis 
4 criteria, compliance was most often achieved by the 
authors reporting that they had not taken measures to 
reduce the risk of bias. While this is not ideal, we believe 
Figure 5 95% CIs, for each item, for the change in performance in NPG (red) and non-NPG (blue) 
cohorts. CONSORT, Consolidated Standards of Reporting Trials; NPG, Nature Publishing Group. 
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this represents an improvement, in terms of the useful-
ness of the research to those who wish to use it, from a 
situation where these issues are not reported at all.
For reports of in vivo research, compliance for rando-
misation, blinding, reporting of exclusions and sample 
size calculations in NPG articles reached 68%, 63%, 31% 
and 64%, respectively. For non-NPG articles the perfor-
mance was 12%, 5%, 12% and 3%. The figures for NPG 
articles are similar to those recently reported for in vivo 
research published in the journal ‘Stroke’,13 14 which began 
requiring reporting of such details following the publi-
cation of good practice guidelines in 2009,15 and where 
performance was found to be substantially higher than 
for in vivo research published in other American Heart 
Association journals.14
While we saw improvements in the transparency 
of reporting, the observed improvements in experi-
mental design were much more modest. However, peer 
review may not ensure the quality of published work,16 
as evidenced for in vivo research by poor reporting of 
measures to reduce risks of bias.1 We believe that the ulti-
mate responsibility for assessing research quality (and 
therefore the validity of the findings presented) rests with 
the reader, and transparency in reporting is fundamental 
to this assessment.
For reports of in vitro research, compliance was 
substantially lower. There have been few systematic 
attempts to measure the quality of reporting of measures 
to reduce the risks of bias in vitro research, and our find-
ings suggest that, both in NPG and non-NPG journals, 
this remains low. There were improvements in reporting 
randomisation, blinding and sample size calculations in 
NPG descriptions of in vitro research, but only to 18%, 
23% and 34%, respectively. For non-NPG the equivalent 
figures were 3%, 1% and 1%. There were no significant 
changes in the reporting of exclusion of in vitro data, with 
postintervention compliance of 16% in NPG articles and 
6% in non-NPG articles.
For other checklist items, changes in performance 
were less dramatic, but there appeared to be incre-
mental improvements across most of the items measured, 
although few of these breached our rather parsimonious 
adjustment for multiple testing. In spite of substantial 
attention given to the importance of reporting the sex 
of experimental animals, this was only done in 52% of 
postintervention NPG studies and in 36% of non-NPG 
studies.
Our assessment of compliance with the checklist 
was based on the resulting manuscript, and not on the 
completed checklists submitted by the study authors, 
which were not available to us for analysis. Therefore, 
we do not know whether these submitted checklists were 
incomplete but the requirement for compliance was not 
completely enforced, or if the authors and editors consid-
ered that manuscripts were compliant but our outcome 
assessors disagreed with those judgements. Knowing the 
relative contribution of these two explanations would 
inform refinements to checklist-based strategies to 
improve reporting. Of note, for the Consolidated Stan-
dards of Reporting Trials checklist, Blanco and colleagues 
recently showed that the checklist as submitted was 
concordant with the manuscript as published for only 
one of six studies.1
Ours is an observational study, and it is possible that 
other (related or unrelated) changes were responsible for 
much if not all the differences seen. These changes were 
not observed in other journals (at least not when taken 
in aggregate), and so it is likely that alternative causal 
factors would relate to NPG editorial policy and practice. 
While we are not aware of any other relevant changes in 
editorial policy occurring at a relevant time, it is likely 
that this change in editorial policy was accompanied by 
increased attention given to the importance of the quality 
of reporting by both inhouse editorial staff and external 
peer reviewers. It is not possible to determine whether 
these might have caused the changes seen. However, a 
randomised controlled study of the effect of the Animal 
Research: Reporting of In Vivo Experiments  (ARRIVE) 
checklist completion on the quality of reporting of in vivo 
research at PLoS One will report shortly.
While our primary outcome measure was unchanged, 
when writing our data analysis plan (and prior to any data 
inspection or analysis), we did change our criterion for 
measuring success, from ‘whether compliance (with the 
Landis 4 criteria, for in vivo research) in the postinter-
vention group of articles reached 80%’ to ‘the change in 
proportion of articles describing in vivo research meeting 
the 4 Landis criteria’. This was because our primary inten-
tion had been to observe any effect of a change in publi-
cation policy, and with the benefit of hindsight this was 
not captured in our original primary outcome, but we 
recognise this as a limitation in our findings. We note, 
however, that the primary outcome used reflects better 
the title of the study protocol than does the primary 
outcome measure proposed in that protocol.
For our comparator group we chose similar articles with 
a similar date of publication identified using the PubMed 
‘related citations’ tool. The journals in which these works 
were published will vary in the attention which they have 
given to transparency in reporting, and it may be that 
for some journals there have been changes similar to 
those observed in the NPG articles. While we might have 
restricted our comparator group to journals more similar 
to NPG articles (for instance by impact factor or extent 
of editorial intervention), this would have meant lower 
fidelity of matching by subject area or date of publica-
tion or both, and we considered these factors to be more 
important. For this reason, our findings for NPG articles 
cannot be interpreted as showing improved reporting 
compared with similar articles in similar journals. The 
representation of such ‘similar’ journals in the compar-
ator group is too small to allow meaningful conclusions 
to be drawn.
During the study we encountered some difficulties 
that we had not expected. We had thought that it would 
be straightforward to distinguish between an in vivo 
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experiment and an in vitro experiment, but we had to 
develop an operational approach which defined that 
experiment on the basis of the subject at the time that 
the experimental intervention occurred; so a tissue slice 
experiment involving tissues from animals exposed to 
treatment or control we considered in vivo, while a similar 
experiment applying drugs directly to the slice we consid-
ered to be an in vitro experiment.
Our matching on whether studies reported in vitro 
or in vivo research or both was also reasonable in 
most cases. Differences will have emerged where, as 
described above, articles were initially categorised with 
one set of characteristics (in vitro, in vivo or both) and 
matched accordingly, but later judged to have different 
characteristics. Our matching for date of publication 
worked reasonably well, apart from the inclusion of 
one comparator article published in 1995, 215 months 
before its ‘matching’ NPG article. We had not antic-
ipated that matching articles would be so difficult to 
identify, so our matching rules did not have an upper 
limit of difference in the date of publication. An alter-
native approach would have been to prioritise matching 
on data of publication rather than manuscript content, 
but each approach has its weaknesses. Because one 
group (non-NPG studies published before May 2013) is 
substantially smaller, this will have limited, to an extent, 
the statistical power of these contrasts; however, since 
power changes with the square root of the number of 
studies, we estimate this loss of power only to be around 
10%. Since the comparator (non-NPG) group does not 
contribute to our primary outcome, and the matching is 
generally good, we do not think that these mismatches 
devalue our findings to any appreciable extent.
Our matching by country of origin in the NPG 
cohort of publications may have introduced a bias in 
that manuscripts from countries with fewer publica-
tions may have been excluded because of the lack of an 
appropriate match. However, the included manuscripts 
had a country of origin matching more than 85% of 
Nature papers published between 2010 and 2016, and 
so it is unlikely that this has introduced major bias.
Further, there were some checklist items where 
agreement between outcome assessors was very low—
for instance, for the question of whether for in vivo 
research the difference in variance between groups 
being compared was less than twofold, the agree-
ment was no better than would be expected by chance 
alone. We recommend that the future development of 
publication checklists should include an assessment of 
interobserver variation by potential users of the check-
list for each checklist item; low agreement might indi-
cate that the item should be rephrased or reframed, or 
that more explanatory text is required.
We encountered a further unexpected problem 
when assessing compliance with reporting of blinding, 
randomisation and with sample size calculations. 
These were assessed with pairs of questions: first did 
the study report doing it (yes/no/not relevant); and 
second did they at least mention it (yes/no/not rele-
vant). If a study was ‘yes’ for the first question, asses-
sors were instructed to score the second as not relevant. 
Therefore, the number scored as ‘not relevant’ for the 
second question should represent the sum of those 
scored as ‘yes’ and as ‘not relevant’ for the first. This 
was not always the case (for in vivo research occurring 
in 0.1%, 0.8% and 6% of assessments for sample size 
calculation, randomisation and blinding, respectively), 
but we did not become aware of this problem until after 
database lock. Any impact of this shortcoming is likely 
to be small.
Finally, our work shows the challenge of assessing even 
a relatively limited number of articles against a relatively 
straightforward checklist. We are delighted that so many 
collaborators (from six continents) agreed to participate 
and are very grateful to them. However, even with their 
help the outcome assessment and reconciliation took 17 
months. This is too slow to be useful, for instance, for 
quality improvement activity, where more rapid feed-
back would allow more rapid adjustments in response 
to performance. We have tested the use of text analytics 
using regular expressions to automatically ascertain 
reporting of measures to reduce the risk of bias, and for 
some such risks of bias the approach achieves sensitiv-
ities and specificities above 80%.17 For more complex 
items it is likely that machine learning approaches using, 
for instance, convoluted neural networks may be more 
successful, and this is a current focus of our research. 
We hope that, by making the data set for this study avail-
able, this might be used, for instance, for distant super-
vised learning in such systems. However, the extent of 
disagreement between our trained assessors suggests 
that the language used to describe experiments in 
biomedicine is not altogether clear, and both machines 
and human may require greater clarity in reporting to 
fully understand published research.
COnClusIOns
Introduction of a checklist leads to substantial improve-
ments in the quality of reporting in NPG articles 
that were not seen in matched articles from other 
publishers, and these improvements appear to be 
ongoing. However, there is still substantial room for 
improvement, which suggests that measures such as 
mandatory author checklists need to be supplemented 
by other approaches.
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